RESILIENCE GOVERNMENT SERVICES, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1999-01-01

Employees: 251

Market Cap: -

Website: https://www.ologybio.com

Clinical Trials

Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

Completed

Conditions: Influenza
Pandemic Influenza

Interventions: Biological: H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)

First Posted Date: 2009-07-31

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 3216

Registration Number: NCT00950456

Locations: 🇦🇹
Medical University of Vienna, Department of Specific Prophylaxis and Tropical Medicine, Vienna, Austria
🇦🇹
Hanusch Hospital, Vienna, Austria
🇦🇹
Wiener Gebietskrankenkasse (Health insurance center Vienna), Vienna, Austria

and more 4 locations

Yearly Strain Variation Study, 2009/2010

Phase 3

Completed

Conditions: Influenza
Seasonal Influenza

First Posted Date: 2009-07-22

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 110

Registration Number: NCT00943657

Locations: 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults

Phase 1

Completed

Conditions: Avian Influenza
Influenza

Interventions: Biological: Influenza vaccine (whole virion, Vero cell derived)

First Posted Date: 2009-05-08

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 231

Registration Number: NCT00895544

Locations: 🇦🇹
General Hospital of Vienna (AKH Wien), Dept. of Clinical Pharmacology, Vienna, Austria
🇫🇮
Espoon rokotetutkumusklinikka, Espoo, Finland
🇫🇮
Etelä - Helsingin rokotetutkimusklinikka, Helsinki, Finland

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Vero cell-derived, trivalent, seasonal influenza vaccine

First Posted Date: 2008-12-02

Last Posted Date: 2015-10-29

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 7252

Registration Number: NCT00800605

Locations: 🇺🇸
Benchmark Research, Metairie, Louisiana, United States
🇺🇸
Quality of Life Medical & Research Center, LLC, Tucson, Arizona, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

and more 32 locations

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Phase 1

Completed

Conditions: Pandemic Influenza
Influenza

Interventions: Biological: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)

First Posted Date: 2008-11-02

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 422

Registration Number: NCT00783926

Locations: 🇺🇸
Heartland Research Associates, LLC, Wichita, Kansas, United States
🇺🇸
Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States
🇺🇸
Rochester Clinical Research, Rochester, New York, United States

and more 3 locations

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Vero cell derived, trivalent, seasonal influenza vaccine
Biological: Licensed egg-derived, trivalent seasonal influenza vaccine

First Posted Date: 2008-10-31

Last Posted Date: 2015-10-29

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 3195

Registration Number: NCT00782431

Locations: 🇺🇸
Coastal Clinical Research, Inc., Mobile, Alabama, United States
🇺🇸
Clinical Research of South Florida, Coral Cables, Florida, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

and more 27 locations

Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine

Phase 1

Completed

Conditions: Ross River Virus Disease (RRVD)

Interventions: Biological: Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant

First Posted Date: 2008-07-18

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 400

Registration Number: NCT00717834

Locations: 🇳🇱
Andromed Leiden, Leiden, Netherlands
🇧🇪
Universiteit Antwerpen VAXINFECTIO, Antwerp, Belgium
🇧🇪
Unité d´Investigation Clinique BioVallée, La Louvière, Belgium

and more 7 locations

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted

First Posted Date: 2008-07-08

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 3583

Registration Number: NCT00711295

Locations: 🇩🇪
Charité - Universitaetsmedizin Berlin, Medizinische Klinik III, Haematologie, Onkologie & Transfusionsmedizin, Karl Landsteiner-Haus, 1 OG, Hindenburgdamm 30, Berlin, Germany
🇩🇪
Johannes Gutenberg-Universitaet, III. Medizinische Klinik und Poliklinik, Langenbeckstr. 1, Mainz, Germany
🇫🇮
Etelä-Helsingin rokotetutkimusklinikka, Vuorikatu 18, 3 krs, Helsinki, Finland

and more 42 locations

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Phase 3

Completed

Conditions: Influenza

Interventions: Other: Phosphate buffered saline
Biological: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)

First Posted Date: 2007-12-03

Last Posted Date: 2023-10-17

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 3670

Registration Number: NCT00566345

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

Phase 2

Completed

Conditions: Influenza

First Posted Date: 2007-09-17

Last Posted Date: 2015-10-09

Lead Sponsor: Resilience Government Services, Inc.

Target Recruit Count: 141

Registration Number: NCT00530660

Locations: 🇦🇹
University Hospital, Department of Clinical Pharmacology, General Hospital Vienna, Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy